Novel PCR Testing Device Represents Technological Leap in POC Infectious Disease Diagnostics
By LabMedica International staff writers Posted on 15 May 2023 |
Testing for infectious diseases is vital for global health. Present testing methods, including immunochemistry and nucleic acid detection, play a crucial role in combating infectious diseases, but they also have significant drawbacks. Consequently, healthcare providers and patients often have to choose between fast and affordable results with limited sensitivity, or slower, more accurate results which often arrive too late to significantly impact outcomes. This situation often leads to lost opportunities for more effective treatment of infectious diseases. Now, a novel testing device offers a significant advancement in point-of-care infectious disease testing, potentially expanding the scope of telemedicine interactions between healthcare professionals and their patients.
Nuclein’s (Austin, TX, USA) Anywhere PCR Test is a PCR testing device designed to run a real-time PCR reaction inside an all-in-one self-test, infectious disease testing solution and delivers battery-powered, sample-to-answer results in less than an hour. This allows immediate, self-testing results to be available anywhere at the push of a button, utilizing the same standard real-time PCR technology employed by the U.S. Centers for Disease Control and Prevention (CDC), other government bodies, and commercial laboratories.
The testing device is designed to accept a saliva sample directly from the patient. The diagnostic process can be initiated by simply pressing a button, after which the device automatically prepares the sample for analysis. Test results are then automatically displayed on the LCD screen within an hour, indicating either a negative or positive result. The capacity to provide immediate results in less than an hour potentially makes the Nuclein Anywhere PCR Test an exceptionally useful tool for detecting infectious diseases, facilitating faster and more informed decision-making, ultimately leading to improved outcomes.
Related Links:
Nuclein
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans